vs
博士伦（BLCO）与National Vision Holdings, Inc.（EYE）财务数据对比。点击上方公司名可切换其他公司
博士伦的季度营收约是National Vision Holdings, Inc.的2.9倍（$1.4B vs $487.3M）。National Vision Holdings, Inc.净利率更高（0.7% vs -4.1%，领先4.8%）。博士伦同比增速更快（9.8% vs 7.9%）。博士伦自由现金流更多（$60.0M vs $30.3M）。过去两年博士伦的营收复合增速更高（13.1% vs 7.6%）
博士伦是知名眼健康产品企业，总部位于加拿大安大略省沃恩市，是全球规模最大的隐形眼镜、镜片护理产品、眼科药品、人工晶体及其他眼科手术产品供应商之一。品牌1853年由验光师约翰·鲍什与合伙人亨利·朗姆在美国纽约罗切斯特创立，曾是美国历史最悠久的持续运营企业之一，2013年被整体收购。
Vision Research是一家总部位于美国新泽西州韦恩的跨国企业，主营高速数码相机的研发生产，旗下产品以Phantom品牌推向市场，广泛应用于国防、工业产品开发、制造、汽车、科研、娱乐等众多领域，目前隶属于全球电子仪器及机电设备制造商阿美特克公司的材料分析事业部。
BLCO vs EYE — 直观对比
营收规模更大
BLCO
是对方的2.9倍
$487.3M
营收增速更快
BLCO
高出1.8%
7.9%
净利率更高
EYE
高出4.8%
-4.1%
自由现金流更多
BLCO
多$29.7M
$30.3M
两年增速更快
BLCO
近两年复合增速
7.6%
损益表 — Q4 2025 vs Q3 2026
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $487.3M |
| 净利润 | $-58.0M | $3.4M |
| 毛利率 | — | — |
| 营业利润率 | 8.0% | 2.0% |
| 净利率 | -4.1% | 0.7% |
| 营收同比 | 9.8% | 7.9% |
| 净利润同比 | -1833.3% | 139.8% |
| 每股收益（稀释后） | $-0.16 | $0.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLCOEYE
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.3B | $487.3M | ||
| Q2 25 | $1.3B | $486.4M | ||
| Q1 25 | $1.1B | $510.3M | ||
| Q4 24 | $1.3B | $437.3M | ||
| Q3 24 | $1.2B | $451.5M | ||
| Q2 24 | $1.2B | $451.7M | ||
| Q1 24 | $1.1B | $482.8M |
净利润BLCOEYE
| Q4 25 | $-58.0M | — | ||
| Q3 25 | $-28.0M | $3.4M | ||
| Q2 25 | $-62.0M | $8.7M | ||
| Q1 25 | $-212.0M | $14.2M | ||
| Q4 24 | $-3.0M | $-28.6M | ||
| Q3 24 | $4.0M | $-8.5M | ||
| Q2 24 | $-151.0M | $-3.1M | ||
| Q1 24 | $-167.0M | $11.7M |
营业利润率BLCOEYE
| Q4 25 | 8.0% | — | ||
| Q3 25 | 7.4% | 2.0% | ||
| Q2 25 | -0.9% | 3.4% | ||
| Q1 25 | -7.3% | 5.1% | ||
| Q4 24 | 6.8% | -5.8% | ||
| Q3 24 | 3.6% | -2.0% | ||
| Q2 24 | 2.1% | 0.1% | ||
| Q1 24 | 0.5% | 4.9% |
净利率BLCOEYE
| Q4 25 | -4.1% | — | ||
| Q3 25 | -2.2% | 0.7% | ||
| Q2 25 | -4.9% | 1.8% | ||
| Q1 25 | -18.6% | 2.8% | ||
| Q4 24 | -0.2% | -6.5% | ||
| Q3 24 | 0.3% | -1.9% | ||
| Q2 24 | -12.4% | -0.7% | ||
| Q1 24 | -15.2% | 2.4% |
每股收益（稀释后）BLCOEYE
| Q4 25 | $-0.16 | — | ||
| Q3 25 | $-0.08 | $0.04 | ||
| Q2 25 | $-0.18 | $0.11 | ||
| Q1 25 | $-0.60 | $0.18 | ||
| Q4 24 | $-0.00 | $-0.36 | ||
| Q3 24 | $0.01 | $-0.11 | ||
| Q2 24 | $-0.43 | $-0.04 | ||
| Q1 24 | $-0.48 | $0.15 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $383.0M | $56.0M |
| 总债务越低越好 | $5.0B | $236.5M |
| 股东权益账面价值 | $6.4B | $858.8M |
| 总资产 | $14.0B | $2.0B |
| 负债/权益比越低杠杆越低 | 0.78× | 0.28× |
8季度趋势，按日历期对齐
现金及短期投资BLCOEYE
| Q4 25 | $383.0M | — | ||
| Q3 25 | $310.0M | $56.0M | ||
| Q2 25 | $266.0M | $48.5M | ||
| Q1 25 | $202.0M | $80.0M | ||
| Q4 24 | $305.0M | $73.9M | ||
| Q3 24 | $329.0M | $81.2M | ||
| Q2 24 | $285.0M | $179.5M | ||
| Q1 24 | $315.0M | $150.1M |
总债务BLCOEYE
| Q4 25 | $5.0B | — | ||
| Q3 25 | $5.0B | $236.5M | ||
| Q2 25 | $5.0B | $255.6M | ||
| Q1 25 | $4.8B | $244.7M | ||
| Q4 24 | $4.8B | $248.6M | ||
| Q3 24 | $4.6B | $252.8M | ||
| Q2 24 | $4.6B | $143.9M | ||
| Q1 24 | $4.6B | $448.6M |
股东权益BLCOEYE
| Q4 25 | $6.4B | — | ||
| Q3 25 | $6.4B | $858.8M | ||
| Q2 25 | $6.4B | $850.6M | ||
| Q1 25 | $6.4B | $836.2M | ||
| Q4 24 | $6.5B | $816.3M | ||
| Q3 24 | $6.6B | $840.0M | ||
| Q2 24 | $6.5B | $843.4M | ||
| Q1 24 | $6.7B | $841.3M |
总资产BLCOEYE
| Q4 25 | $14.0B | — | ||
| Q3 25 | $13.8B | $2.0B | ||
| Q2 25 | $13.8B | $2.0B | ||
| Q1 25 | $13.4B | $2.0B | ||
| Q4 24 | $13.5B | $2.0B | ||
| Q3 24 | $13.5B | $2.0B | ||
| Q2 24 | $13.3B | $2.1B | ||
| Q1 24 | $13.3B | $2.2B |
负债/权益比BLCOEYE
| Q4 25 | 0.78× | — | ||
| Q3 25 | 0.77× | 0.28× | ||
| Q2 25 | 0.77× | 0.30× | ||
| Q1 25 | 0.76× | 0.29× | ||
| Q4 24 | 0.74× | 0.30× | ||
| Q3 24 | 0.70× | 0.30× | ||
| Q2 24 | 0.71× | 0.17× | ||
| Q1 24 | 0.69× | 0.53× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $136.0M | $46.6M |
| 自由现金流经营现金流 - 资本支出 | $60.0M | $30.3M |
| 自由现金流率自由现金流/营收 | 4.3% | 6.2% |
| 资本支出强度资本支出/营收 | 5.4% | 3.4% |
| 现金转化率经营现金流/净利润 | — | 13.83× |
| 过去12个月自由现金流最近4个季度 | $-66.0M | $83.0M |
8季度趋势，按日历期对齐
经营现金流BLCOEYE
| Q4 25 | $136.0M | — | ||
| Q3 25 | $137.0M | $46.6M | ||
| Q2 25 | $35.0M | $54.3M | ||
| Q1 25 | $-25.0M | $32.2M | ||
| Q4 24 | $22.0M | $30.3M | ||
| Q3 24 | $154.0M | $27.9M | ||
| Q2 24 | $15.0M | $51.5M | ||
| Q1 24 | $41.0M | $24.0M |
自由现金流BLCOEYE
| Q4 25 | $60.0M | — | ||
| Q3 25 | $63.0M | $30.3M | ||
| Q2 25 | $-54.0M | $42.4M | ||
| Q1 25 | $-135.0M | $12.0M | ||
| Q4 24 | $-70.0M | $-1.7M | ||
| Q3 24 | $94.0M | $4.1M | ||
| Q2 24 | $-57.0M | $31.9M | ||
| Q1 24 | $-26.0M | $4.0M |
自由现金流率BLCOEYE
| Q4 25 | 4.3% | — | ||
| Q3 25 | 4.9% | 6.2% | ||
| Q2 25 | -4.2% | 8.7% | ||
| Q1 25 | -11.9% | 2.4% | ||
| Q4 24 | -5.5% | -0.4% | ||
| Q3 24 | 7.9% | 0.9% | ||
| Q2 24 | -4.7% | 7.1% | ||
| Q1 24 | -2.4% | 0.8% |
资本支出强度BLCOEYE
| Q4 25 | 5.4% | — | ||
| Q3 25 | 5.8% | 3.4% | ||
| Q2 25 | 7.0% | 2.4% | ||
| Q1 25 | 9.7% | 4.0% | ||
| Q4 24 | 7.2% | 7.3% | ||
| Q3 24 | 5.0% | 5.3% | ||
| Q2 24 | 5.9% | 4.3% | ||
| Q1 24 | 6.1% | 4.1% |
现金转化率BLCOEYE
| Q4 25 | — | — | ||
| Q3 25 | — | 13.83× | ||
| Q2 25 | — | 6.22× | ||
| Q1 25 | — | 2.27× | ||
| Q4 24 | — | — | ||
| Q3 24 | 38.50× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 2.05× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLCO
| Overthe Counter Products | $489.0M | 35% |
| Pharmaceuticals | $378.0M | 27% |
| Other | $263.0M | 19% |
| Surgical | $249.0M | 18% |
| Brandedand Other Generic Products | $14.0M | 1% |
| Other Revenues | $3.0M | 0% |
| Pharmaceutical Products | $2.0M | 0% |
EYE
暂无分部数据
